Analysts have been eager to weigh in on the Healthcare sector with new ratings on SAGE Therapeutics (SAGE – Research Report), Accolade (ACCD – Research Report) and Intuitive Surgical (ISRG – Research Report).
SAGE Therapeutics (SAGE)
Leerink Partners analyst Marc Goodman maintained a Hold rating on SAGE Therapeutics on April 17. The company’s shares closed last Friday at $13.33, close to its 52-week low of $10.92.
According to TipRanks.com, Goodman is a 3-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for SAGE Therapeutics with a $21.77 average price target, which is a 68.4% upside from current levels. In a report issued on April 4, RBC Capital also maintained a Hold rating on the stock with a $26.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Accolade (ACCD)
Leerink Partners analyst Michael Cherny maintained a Buy rating on Accolade on April 18 and set a price target of $16.00. The company’s shares closed last Friday at $9.13.
According to TipRanks.com, Cherny is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Accolade with a $14.33 average price target.
Intuitive Surgical (ISRG)
In a report issued on April 18, Mike Kratky from Leerink Partners reiterated a Buy rating on Intuitive Surgical, with a price target of $449.00. The company’s shares closed last Friday at $366.34.
According to TipRanks.com, Kratky is a 4-star analyst with an average return of
Currently, the analyst consensus on Intuitive Surgical is a Moderate Buy with an average price target of $423.59, which is a 9.9% upside from current levels. In a report issued on April 8, Stifel Nicolaus also maintained a Buy rating on the stock with a $430.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SAGE:
- Biotech Alert: Searches spiking for these stocks today
- SAGE Therapeutics Adjusts Inducement Equity Plan and Sets End Date
- Sage Therapeutics price target lowered to $19 from $34 at Scotiabank
- Sage Therapeutics price target lowered to $17 from $25 at Oppenheimer
- H.C. Wainwright concerned over Sage’s next readouts after SAGE-718 miss
